Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
Authors:
Open Access
- 8 May 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (30) , 49451-49469
Abstract
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cellsKeywords
This publication has 37 references indexed in Scilit:
- MicroRNAs in myeloid malignanciesBritish Journal of Haematology, 2013
- Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatmentBlood, 2011
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityJournal of Clinical Investigation, 2011
- Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinibBlood, 2009
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosisNucleic Acids Research, 2005
- MicroRNAs Modulate Hematopoietic Lineage DifferentiationScience, 2004
- bantam Encodes a Developmentally Regulated microRNA that Controls Cell Proliferation and Regulates the Proapoptotic Gene hid in DrosophilaCell, 2003
- Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitroBlood, 2002
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999